scholarly journals High Prognostic Significance of Residual Disease After Neoadjuvant Chemotherapy: a Retrospective Study in 710 Patients with Operable Breast Cancer

2006 ◽  
Vol 98 (3) ◽  
pp. 365-365
Author(s):  
Sophie Catherine Abrial ◽  
Frédérique Penault-Llorca ◽  
Rémi Delva ◽  
Philippe Bougnoux ◽  
Bernard Leduc ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Retrospective Study ◽  
Neoadjuvant Chemotherapy ◽  
Residual Disease ◽  
Prognostic Significance ◽  
Operable Breast Cancer

High prognostic significance of residual disease after neoadjuvant chemotherapy: a retrospective study in 710 patients with operable breast cancer

2005 ◽  
Vol 94 (3) ◽  
pp. 255-263 ◽  
Author(s):  
Sophie Catherine Abrial ◽  
Frédérique Penault-Llorca ◽  
Rémi Delva ◽  
Philippe Bougnoux ◽  
Bernard Leduc ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Retrospective Study ◽  
Neoadjuvant Chemotherapy ◽  
Residual Disease ◽  
Prognostic Significance ◽  
Operable Breast Cancer

Prognostic Factors in Operable Breast Cancer Treated with Neoadjuvant Chemotherapy: Towards a Quantification of Residual Disease

Oncology ◽  
2015 ◽  
Vol 88 (5) ◽  
pp. 261-272 ◽  
Author(s):  
Sarah Mombelli ◽  
Fabrice Kwiatkowski ◽  
Catherine Abrial ◽  
Qian Wang-Lopez ◽  
Paul de Boissieu ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Prognostic Factors ◽  
Neoadjuvant Chemotherapy ◽  
Residual Disease ◽  
Operable Breast Cancer

Prognostic Significance of Neutropenia on Day One of Anthracycline-Based Neoadjuvant Chemotherapy in Operable Breast Cancer

Oncology ◽  
2010 ◽  
Vol 78 (3-4) ◽  
pp. 213-219 ◽  
Author(s):  
Makoto Ishitobi ◽  
Yoshifumi Komoike ◽  
Kazuyoshi Motomura ◽  
Hiroki Koyama ◽  
Hideo Inaji
Keyword(s):  
Breast Cancer ◽  
Neoadjuvant Chemotherapy ◽  
Prognostic Significance ◽  
Operable Breast Cancer

scholarly journals Prognostic significance of pathological complete response following neoadjuvant chemotherapy for operable breast cancer

2014 ◽  
Vol 7 (3) ◽  
pp. 663-668 ◽  
Author(s):  
HIDEMI KAWAJIRI ◽  
TSUTOMU TAKASHIMA ◽  
NAOKI AOMATSU ◽  
SHINICHIRO KASHIWAGI ◽  
SATORU NODA ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Neoadjuvant Chemotherapy ◽  
Pathological Complete Response ◽  
Prognostic Significance ◽  
Complete Response ◽  
Operable Breast Cancer

Prognosefaktoren bei operablem Brustkrebs unter neoadjuvanter Chemotherapie: Auf dem Weg zu einer Quantifizierung der Residualerkrankung

2015 ◽  
Vol 2 (2) ◽  
pp. 86-87
Keyword(s):  
Breast Cancer ◽  
Prognostic Factors ◽  
Neoadjuvant Chemotherapy ◽  
Adjuvante Therapie ◽  
Residual Disease ◽  
Prognostische Faktoren ◽  
Operable Breast Cancer ◽  
Neoadjuvante Chemotherapie ◽  
Multivariate Analysen

Ziel: Die neoadjuvante Chemotherapie (NACT) ermöglicht es, häufiger brusterhaltend zu operieren; außerdem stellt sie ein In-vivo-Modell für die individuelle Tumorsensitivität dar und erlaubt so die Erkennung neuer prognostischer Faktoren für die Personalisierung der Therapie. Methoden: Zwischen 2000 und 2012 wurden 318 Patientinnen mit primärem invasivem Mammakarzinom mit im Median 6 Zyklen NACT behandelt; sie erhielten entweder ein anthracyklinhaltiges FEC-100-Protokoll (31,1%) oder Anthracykline + Taxane (53,5%), bei entsprechender Indikation zusätzlich auch Trastuzumab (15,4%). Ergebnisse: Nach einer medianen Nachbeobachtungszeit von 44,2 Monaten betrug die Rate pathologisch gesicherter Vollremissionen gemäß der Klassifikation von Chevallier et al. (Am J Clin Oncol 1993;16:223-228) 19,3%, und die 10-Jahres-Raten des Gesamtüberlebens (OS) und des krankheitsfreien Überlebens (DFS) betrugen 60,2 bzw. 69,6%. Univariate Analysen belegten, dass der RDBN-Index (RDBN = Residual Disease in Breast and Nodes) der signifikanteste Prognosefaktor für das OS (p = 0,0082) und DFS war (p = 0,0022), während multivariate Analysen vor allem ergaben, dass das Volumen des Residualtumors, die Anzahl residualer befallener Lymphknoten sowie der Scarff-Bloom-Richardson(SBR)-Grad nach Chemotherapie die signifikantesten prognostischen Faktoren waren. Schlussfolgerungen: In einer Kohorte von Patientinnen, die allesamt mit einigen der gängigsten medikamentösen Brustkrebs-Therapien behandelt wurden, wiesen wir nach, dass eine NACT zusätzliche prognostische Faktoren liefern und den RDBN-Index bestätigen kann. Da dieser Index wiederum Vorhersagen in Bezug auf das Überleben bei verschiedenen Brustkrebs-Subtypen erlaubt, schlagen wir vor, ihn standardmäßig zu berechnen, um Kliniker bei der Auswahl von Kandidatinnen für eine adjuvante Therapie zu unterstützen. Übersetzung aus Mombelli S, et al: Prognostic factors in operable breast cancer treated with neoadjuvant chemotherapy: towards a quantification of residual disease. Oncology 2015;88:261-272 (DOI: 10.1159/000368557)

scholarly journals Prognostic Significance of Modified Residual Disease in Breast and Nodes (mRDBN) Algorithm After Neoadjuvant Chemotherapy for Breast Cancer

2018 ◽  
Vol 149 (4) ◽  
pp. 332-343
Author(s):  
Beth Z Clark ◽  
Daniel J Farrugia ◽  
Alessandra Landmann ◽  
Emilia J Diego ◽  
David J Dabbs ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Neoadjuvant Chemotherapy ◽  
Residual Disease ◽  
Prognostic Significance

scholarly journals Ki67 Index Changes and Tumor-Infiltrating Lymphocyte Levels Impact the Prognosis of Triple-Negative Breast Cancer Patients With Residual Disease After Neoadjuvant Chemotherapy

2021 ◽  
Vol 11 ◽  
Author(s):  
Yihua Wang ◽  
Beige Zong ◽  
Yu Yu ◽  
Yu Wang ◽  
Zhenrong Tang ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Neoadjuvant Chemotherapy ◽  
Triple Negative Breast Cancer ◽  
Triple Negative ◽  
Residual Disease ◽  
Prognostic Significance ◽  
Ki67 Index ◽  
Breast Cancer Patients ◽  
Prognostic Information ◽  
Index Changes

PurposeThe aim of this study was to assess the prognostic influence of Ki67 index changes in patients with primary triple-negative breast cancer (TNBC) treated with neoadjuvant chemotherapy (NAC), and to evaluate whether the combination of Ki67 index changes and residual disease (RD) tumor-infiltrating lymphocytes (TILs) provides additional prognostic information for this group.Materials and MethodsData from 109 patients with primary TNBC and RD after NAC were analyzed retrospectively. Ki67 changes and RD TIL levels were investigated for associations with recurrence-free survival (RFS) and overall survival (OS) using Kaplan–Meier and Cox analyses.ResultsKi67 index decreased after NAC in 53 patients (48.6%) and high RD TIL levels (≥30%) were observed in 54 patients (49.5%). In multivariate Cox analyses, no Ki67 decrease status and low RD TIL levels were significantly associated with reduced RFS (hazard ratio (HR): 2.038, 95% confidence interval (CI): 1.135–3.658, P = 0.017; HR: 2.493, 95% CI: 1.335–4.653, P = 0.004), and OS (HR: 2.187, 95% CI: 1.173–4.077, P = 0.014; HR: 2.499, 95% CI: 1.285–4.858, P = 0.007), respectively. Notably, low RD TIL levels were significantly associated with reduced RFS (HR: 3.567, 95% CI: 1.475–8.624, P = 0.005) and reduced OS (HR: 3.873, 95% CI: 1.512–9.918, P = 0.005) in only the no Ki67 decrease group. The differences in 3-year RFS and OS between patients with no Ki67 decrease and low or high RD TIL levels were 24.4% vs 79.1% (P = 0.0001) and 33.1% vs 87.5% (P = 0.0001), respectively.ConclusionKi67 index changes and RD TIL levels were associated with the prognosis of patients with primary TNBC with RD after NAC. RD TIL levels had greater prognostic significance in the no Ki67 decrease group.

Comparison of the prognostic significance of Chevallier and Sataloff's pathologic classifications after neoadjuvant chemotherapy of operable breast cancer

2008 ◽  
Vol 39 (8) ◽  
pp. 1221-1228 ◽  
Author(s):  
Frederique Penault-Llorca ◽  
Catherine Abrial ◽  
Ines Raoelfils ◽  
Anne Cayre ◽  
Marie-Ange Mouret-Reynier ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Neoadjuvant Chemotherapy ◽  
Prognostic Significance ◽  
Operable Breast Cancer
Sign in / Sign up

Export Citation Format

Share Document